Result of AGM

SkinBioTherapeutics PLC

29 December 2025

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Group")

Result of Annual General Meeting

29 December 2025 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), a life science company focused on skin health, held its Annual General Meeting today and all resolutions were passed.

Resolution	Votes For		Votes Against		Votes Withheld
1. To receive the annual report and accounts	88,024,558	83.50%	17,391,981	16.50%	722,198
2. To re-appoint Gravita as auditor	96,998,314	92.15%	8,266,920	7.85%	873,503
3. To authorise Directors to determine Auditors renumeration	97,093,358	92.13%	8,296,876	7.87%	748,503
4. To authorise the Directors to allot relevant securities	85,828,638	80.90%	20,268,099	19.10%	42,000
5. To authorise the Directors to allot equity securities for cash without a pre-emptive offer to shareholders	85,771,888	80.84%	20,324,849	19.16%	42,000
6. To authorise the Directors to allot equity securities for cash in relation to an acquisition of other capital investment	85,782,499	81.34%	19,682,546	18.66%	673,692

An electronic copy of the Annual Report and Accounts is available and the results of the AGM will be available on the Company's website in due course at www.skinbiotherapeutics.com/investor-relations.

-Ends-

For more information please contact:

SkinBioTherapeutics plc Stuart J. Ashman, CEO Emily Bertram, Group Finance Director	[phone]
Singer Capital Markets (Nominated Adviser & Broker) Philip Davies Andrew Johnson James Todd	[phone]
Vigo Consulting (financial press) Rozi Morris, Melanie Toyne-Sewell	[phone] [e-mail]

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix^®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix^®) and food supplements that harness the gut-skin axis (AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where SkinBiotix^® is being used as an active skin ingredient with the Croda trade name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the High Street in selected Superdrug Stores plc stores.

The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products. 

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com.

 

END